<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110355</url>
  </required_header>
  <id_info>
    <org_study_id>20120238</org_study_id>
    <nct_id>NCT02110355</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma</brief_title>
  <official_title>A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in&#xD;
      combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a&#xD;
      direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib&#xD;
      combined with dabrafenib alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 3 parts: Part 1 - Dose Escalation, Part 2 - Dose Expansion and&#xD;
      Part 3, a randomized Phase 2a.&#xD;
&#xD;
      In both part 1 and 2, subjects will be enrolled open-label into 1 of 2 arms. For both Arm 1&#xD;
      and Arm 2, the part 1 dose escalation is aimed at determining an AMG 232 maximum tolerated&#xD;
      dose (MTD) with a fixed dose of the combination drug(s) and evaluating safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of each combination. Part 2 dose expansion will enroll&#xD;
      subjects to receive therapy with a dose and schedule of AMG 232 selected from the&#xD;
      corresponding part 1 dose escalation. In part 2 subjects will be enrolled to confirm safety&#xD;
      and tolerability and to assess clinical activity prior to proceeding to Part 3, Phase 2a. In&#xD;
      Phase 2a, Subjects will be randomized open-label in a 1:1 ratio to receive AMG 232 in&#xD;
      combination with trametinib plus dabrafenib versus trametinib plus dabrafenib alone.&#xD;
&#xD;
      Only Part 1 of the study was enrolled and the study did not proceed into Phase 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2014</start_date>
  <completion_date type="Actual">December 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Objective Tumor Response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 of Part 1 and 2 and Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 of Part 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 232</intervention_name>
    <description>Given as an oral tablet in escalating doses</description>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib is an anti-cancer agent</description>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib is an anti-cancer agent</description>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must have histologically or cytologically confirmed metastatic&#xD;
        cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication,&#xD;
        Adequate hematological, renal, hepatic, and coagulation laboratory assessments Exclusion&#xD;
        Criteria: Clinically significant bleeding within 4 weeks of screening, Current use of&#xD;
        warfarin, factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring&#xD;
        anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major&#xD;
        surgery within 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mei</last_name>
    <role>Study Director</role>
    <affiliation>Kartos Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

